CAN-3110
AXP000087.1 · Oncolytic virus
- Platform
- HSV-1 (strain F, nestin-promoter ICP34.5)
- Originator
- Brigham and Women's Hospital (E. Antonio Chiocca)
- Sponsor
- Candel Therapeutics
Names
| Name | Type | Source |
|---|---|---|
| CAN-3110 | preferred name, code | curator, ctgov |
| rQNestin34.5v.2 | code | ctgov |
| rQNestin ambiguous | synonym | ctgov |
Virus
- Role
- Oncolytic
- Family
- Orthoherpesviridae
- Virus
- herpes simplex virus 1 (NCBI Taxonomy 10298)
- Strain
- F
- Replication
- conditionally replicating
- Modifications
- one ICP34.5 copy re-inserted under the nestin promoter; UL39 (ICP6) disrupted by a GFP cassette
- Transgenes
- GFP
- Route
- intratumoral, intracerebral
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT03152318 | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 | Active not recruiting | Phase 1 | 2017-07-18 | 2027-01 | 62 | Anaplastic Oligodendroglioma of Brain (Diagnosis); Astrocytoma; Brain Cancer; Brain Tumor; Ependymoma; Ganglioglioma; Glioblastoma; Glioblastoma Multiforme; Glioma; Malignant Astrocytoma; Malignant Glioma of Brain; Mixed Oligo-Astrocytoma; Oligodendroglioma; Pylocytic/Pylomyxoid Astrocytoma |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41679299 | Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial. | Cell | 2026 | cited by trial NCT03152318 |
| PMID 38853689 | Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy. | Neuro-oncology | 2024 | cited by trial NCT03152318 |
| PMID 37853118 | Clinical trial links oncolytic immunoactivation to survival in glioblastoma. | Nature | 2023 | cited by trial NCT03152318 |
| PMID 35022322 | NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor Immunotherapy. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2022 | cited by trial NCT03152318 |
| PMID 32373649 | Preclinical Toxicology of rQNestin34.5v.2: An Oncolytic Herpes Virus with Transcriptional Regulation of the ICP34.5 Neurovirulence Gene. | Molecular therapy. Methods & clinical development | 2020 | cited by trial NCT03152318 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41411618 | Oncolytic HSV-1-Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis. | Cancer research | 2026 | name in abstract: CAN-3110 |
| PMID 41506791 | CD73 blockade enhances antitumor efficacy of oHSV in solid tumors by increasing macrophage-mediated antigen presentation. | Journal for immunotherapy of cancer | 2026 | name in abstract: CAN-3110 |
| PMID 41689740 | Clinical outcomes in recurrent glioblastoma with oncolytic virotherapy: a review. | Molecular biology reports | 2026 | name in abstract: CAN-3110 |
| PMID 42310302 | IDH1-R132H enhances oncolytic HSV-1 therapy by facilitating viral entry and immune activation in glioma. | Nature communications | 2026 | name in abstract: rQNestin34.5v.2 |
| PMID 42732006 | Development and preclinical evaluation of a decoy DLL4-encoding oncolytic HSV-1 for high-grade glioma. | Oncogene | 2026 | name in abstract: CAN-3110 |
| PMID 41061048 | Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses. | Science translational medicine | 2025 | name in abstract: CAN-3110 |
| PMID 38806994 | A viral attack on brain tumors: the potential of oncolytic virus therapy. | Journal of neurovirology | 2024 | name in abstract: rQNestin34.5v.2 |
| PMID 34004331 | Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme. | Seminars in cancer biology | 2022 | name in abstract: rQNestin34.5v.2 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| P01CA163205 | Project 3: Circumventing extracellular Adenosine barrier to oncolytic virotherapy | BRIGHAM AND WOMEN'S HOSPITAL | KAUR, BALVEEN | 2023–2026 | name in abstract: rQNestin34.5v.2 |
| U01NS061811 | Preclinical Toxicity Evaluation of a Potent Oncolytic Virus | BRIGHAM AND WOMEN'S HOSPITAL | CHIOCCA, E. ANTONIO | 2008–2012 | name in abstract: rQNestin34.5v.2 |
Notes
rQNestin34.5v.2: ICP34.5 restored but placed under the nestin promoter, so replication is limited to nestin-expressing glioma cells. Phase 1 with cyclophosphamide (NCT03152318); results in Nature 2023.
How to cite
CAN-3110 (AXP000087.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000087.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.